ESMO Immuno Oncology Congress 2017: Abstracts

Abstracts 

 

Abstract submission deadlines

Deadline Date and time
Abstracts
Intent to submit LBA
Trial in Progress
Extended deadline: 2 October 2017, 12:00 CEST (Central European Summer Time)
Final Late-breaking abstracts (LBA) 3 November 2017, 21:00 CET (Central European Time)

Outcome notifications

Outcome notifications will be made available to first authors around mid-October 2017.

Late breaking abstracts

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 2 October 2017 will be considered for late-breaking status.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline.

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 3 November 2017, 21:00 CET (Central EuropeanTime)

The final late-breaking abstract deadline of 3 November 2017 is under no circumstances to be considered as an extension of the general submission deadline.

Trial in Progress abstracts

Trial in Progress abstracts in all phases of clinical research (phases I to III) may be submitted.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

  • Background
  • Trial design

Notes:

  • Recruitment must have already begun or have been completed by the abstract submission deadline of 27 September 2017.
  • Abstracts including results or preliminary data will be rejected.

Trial in Progress abstracts may not be considered for Proffered Paper (oral) presentation.

Presentation options for accepted abstracts

The ESMO Immuno Oncology Congress 2017 Scientific Committee will select abstracts for presentation and determine the format of the presentations from the following possibilities:

  • Proffered paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Poster – An important method for communicating details of scientific research, posters will be on display for the duration of the Congress.

Publication of accepted abstracts

Abstracts accepted for presentation at ESMO IO 2017 as Proffered Paper (oral presentation, suffix 'O'), Poster Discussion (suffix 'PD') and Poster (suffix 'P') will be published online on the ESMO website at 12:00 CET on Monday, 4 December 2017.

Late-breaking abstracts (prefix 'LBA') and abstracts selected for the official ESMO IO 2017 Press Programme (additional suffix '_PR') will be made public at the beginning of the official Congress session during which they are presented OR at the beginning of the ESMO Press Conference, whichever is earlier.

All accepted abstracts will be published in the ESMO Immuno Oncology Congress 2017 Abstract Book, a supplement of the official ESMO journal Annals of Oncology.

Travel grants

A restricted number of travel grants to the ESMO Immuno Oncology Congress 2017 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the Scientific Committee on a competitive basis from among the accepted abstracts.

To apply for a travel grant, the following documents must be received by the ESMO Congress Department on or before 2 October 2017:

  • A letter of introduction by the applicant. Please include the following general information:
    • How relevant are the topics presented during this Congress to your current practice and research?
    • Have you attended any event on a similar topic in the last 3 years?
    • How do you believe your attendance at this Congress will help you improve your knowledge in the field and your professional development?
    • How do you consider that the findings published in your abstract make a relevant contribution to the topics presented during this Congress?
    • Have you recently been awarded an ESMO travel grant? If yes, for which event?
  • A copy of the submitted abstract (the applicant must be the first author and presenter)
  • A readable photocopy of either your identity card or passport
  • A short curriculum vitae (maximum 2 pages)

Documentation must be sent by e-mail to travelgrants@esmo.org or, if strictly necessary, by fax to +41 91 973 1918.

ESMO will provide recipients with a subsidised travel ticket, subsidised accommodation and Congress registration.

Travel grant recipients must submit a report detailing the benefits of participating in the ESMO Immuno Oncology Congress 2017 by 7 January 2018.

Incomplete applications will not be considered.